Strides Pharma Science Limited — Investor Meet, 29-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Strides Pharma Science Limited reported a strong quarterly performance in Q2 FY '25, achieving a significant revenue growth, particularly in the US market, driven by new product launches. EBITDA reached INR 236 crores, establishing a record. The company anticipates continued growth, with guidance trending towards the higher end of previous forecasts. New markets and product approvals are expected to further enhance financial performance. Investment in capacity expansion and innovative projects is ongoing, positioning Strides for robust future growth.